Advancis Pharmaceutical has received approval from the FDA to market its antibiotic Keflex in two new strengths, the company said.
Keflex (cephalexin capsules, USP) will now be available in 333-mg and 750-mg tablets. The latter will be a more convenient way to prescribe a 1500-mg daily dosage -- the most common one issued used by doctors -- than the current 250-mg and 500-mg tablets, the company said. Advancis expects to begin marketing the new strengths in July.
Keflex, a first generation cephalosporin antibiotic, is used in the treatment of the respiratory tract infections, otitis media, skin and skin structure infections, bone infections and genitourinary tract infections.